{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:09:45Z","timestamp":1784225385958,"version":"3.55.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Infants frequently receive metronidazole at variable doses and duration for surgical site infection prophylaxis and treatment of intra-abdominal infections. Seizures are a rare (but potentially devastating) side effect of metronidazole, yet the prevalence of seizures in infants, as well as the relationship with metronidazole dose and exposure, are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We examined the Pediatrix Clinical Data Warehouse for infants in neonatal intensive care units from 1997 to 2018 who received at least 1 dose of metronidazole during their first 120 days of life. We used an existing population pharmacokinetic model to simulate exposure parameters, estimating multivariable associations between metronidazole dosing and exposure parameters, and the occurrence of seizure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There were 19,367 intravenous doses of metronidazole given to 1546 infants, and 31 experienced a seizure. Infants with a seizure had a longer median (interquartile values) duration of metronidazole exposure than those without (11 days [6, 15] vs. 7 [4, 11],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). Each added day of metronidazole (OR = 1.06, 95% CI: 1.02\u20131.10), and each standard deviation increase in cumulative area under the plasma concentration\u2212time curve (OR = 1.27, 95% CI: 1.11\u20131.45) were associated with increased odds of seizure. Higher simulated maximum plasma concentration was associated with lower odds of seizure (OR = 0.88, 95% CI: 0.81\u20130.96).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Longer metronidazole exposure and higher cumulative exposure could be associated with increased odds of infant seizures. Using a large observational dataset allowed us to identify a rare adverse event, but prospective studies are needed to validate this finding and further characterize metronidazole dose- and exposure-safety relationships.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000003726","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T16:00:29Z","timestamp":1665072029000},"page":"27-31","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Exposure-response Relationships of Metronidazole in Infants: Integration of Electronic Health Record Data With Population Pharmacokinetic Modeling-derived Exposure Simulation"],"prefix":"10.1097","volume":"42","author":[{"given":"Sarah Jane","family":"Commander","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Surgery, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, School of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Wu","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Lane","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reese H.","family":"Clark","sequence":"additional","affiliation":[{"name":"The MEDNAX Center for Research, Education, Quality and Safety, Sunrise, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel G.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, School of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph P.","family":"Hornik","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, School of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"R1-20260716","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/sur.2016.163","article-title":"Variability in antibiotic regimens for surgical necrotizing enterocolitis highlights the need for new guidelines.","volume":"18","author":"Blackwood","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"R2-20260716","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01.sla.0000164181.67862.7f","article-title":"Postoperative outcomes of extremely low birth-weight infants with necrotizing enterocolitis or isolated intestinal perforation: a prospective cohort study by the NICHD Neonatal Research Network.","volume":"241","author":"Blakely","year":"2005","journal-title":"Ann Surg"},{"key":"R3-20260716","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1128\/AAC.06071-11","article-title":"Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants.","volume":"56","author":"Cohen-Wolkowiez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20260716","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1542\/peds.2010-0807","article-title":"Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling.","volume":"127","author":"Suyagh","year":"2011","journal-title":"Pediatrics"},{"key":"R6-20260716","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000485915","article-title":"Convulsive seizures as presenting symptom of metronidazole-induced encephalopathy: a case report.","volume":"10","author":"S\u00f8rensen","year":"2018","journal-title":"Case Rep Neurol"},{"key":"R7-20260716","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/WNF.0b013e3182334b35","article-title":"Metronidazole-induced central nervous system toxicity: a systematic review.","volume":"34","author":"Kuriyama","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"R8-20260716","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/postgradmedj-2018-136353","article-title":"Convulsive seizures caused by metronidazole-induced encephalopathy.","volume":"95","author":"Ueno","year":"2019","journal-title":"Postgrad Med J"},{"key":"R9-20260716","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1542\/peds.2010-3487","article-title":"Extrapolation of adult data and other data in pediatric drug-development programs.","volume":"128","author":"Dunne","year":"2011","journal-title":"Pediatrics"},{"key":"R10-20260716","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/FTD.0000000000000313","article-title":"Therapeutic drug monitoring, electronic health records, and pharmacokinetic modeling to evaluate sirolimus drug exposure-response relationships in renal transplant patients.","volume":"38","author":"Zimmerman","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R11-20260716","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jpeds.2016.07.011","article-title":"Electronic health records and pharmacokinetic modeling to assess the relationship between ampicillin exposure and seizure risk in neonates.","volume":"178","author":"Hornik","year":"2016","journal-title":"J Pediatr"},{"key":"R12-20260716","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/INF.0000000000001610","article-title":"Use of population pharmacokinetics and electronic health records to assess piperacillin-tazobactam safety in infants.","volume":"36","author":"Salerno","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20260716","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clp.2010.01.016","article-title":"The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system\u2013tools for \u201cmeaningful use\u201d in continuous quality improvement.","volume":"37","author":"Spitzer","year":"2010","journal-title":"Clin Perinatol"},{"key":"R14-20260716","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/INF.0b013e3182947cf8","article-title":"Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants.","volume":"32","author":"Cohen-Wolkowiez","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20260716","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/B978-0-444-64029-1.00017-5","article-title":"Seizure classification, etiology, and management.","volume":"162","author":"Shellhaas","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"R17-20260716","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1055\/s-0039-1693149","article-title":"Neonatal seizures-are we there yet?","volume":"50","author":"Ramantani","year":"2019","journal-title":"Neuropediatrics"},{"issue":"3 Pt 1","key":"R18-20260716","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.45.3.588","article-title":"Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy.","volume":"45","author":"Ahmed","year":"1995","journal-title":"Neurology"},{"key":"R19-20260716","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000046052","article-title":"Metronidazole-induced encephalopathy in a uremic patient: a case report.","volume":"89","author":"Arik","year":"2001","journal-title":"Nephron"},{"key":"R20-20260716","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/0091270010362905","article-title":"Metronidazole-induced encephalopathy: a case report and review of the literature.","volume":"51","author":"Bottenberg","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R21-20260716","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/106002809002400103","article-title":"Persistent metronidazole-induced peripheral neuropathy.","volume":"24","author":"Boyce","year":"1990","journal-title":"DICP"},{"key":"R22-20260716","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/00004728-200211000-00016","article-title":"Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.","volume":"26","author":"Cecil","year":"2002","journal-title":"J Comput Assist Tomogr"},{"key":"R23-20260716","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1017\/S0317167100011951","article-title":"Metronidazole-induced encephalopathy: case report and review of MRI findings.","volume":"38","author":"Desai","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"R24-20260716","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neurol.2008.10.026","article-title":"[Metronidazole-related polyneuritis, convulsive seizures, and cerebellar syndrome. Contribution of MRI].","volume":"165","author":"Ferroir","year":"2009","journal-title":"Rev Neurol (Paris)"},{"key":"R25-20260716","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neurad.2007.01.127","article-title":"Reversible metronidazole-induced encephalopathy.","volume":"34","author":"Hammami","year":"2007","journal-title":"J Neuroradiol"},{"key":"R26-20260716","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1345\/aph.10028","article-title":"Toxic metronidazole-induced MRI changes.","volume":"34","author":"Horlen","year":"2000","journal-title":"Ann Pharmacother"},{"key":"R27-20260716","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1552-6569.2004.tb00266.x","article-title":"Reversible cerebellar lesions induced by metronidazole therapy for helicobacter pylori.","volume":"14","author":"Ito","year":"2004","journal-title":"J Neuroimaging"},{"key":"R28-20260716","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jns.2004.06.012","article-title":"Metronidazole-induced encephalopathy.","volume":"224","author":"Kim","year":"2004","journal-title":"J Neurol Sci"},{"key":"R29-20260716","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3174\/ajnr.A0655","article-title":"MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings.","volume":"28","author":"Kim","year":"2007","journal-title":"AJNR Am J Neuroradiol"},{"key":"R30-20260716","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.ijid.2008.03.006","article-title":"Cerebellar ataxia following prolonged use of metronidazole: case report and literature review.","volume":"12","author":"Patel","year":"2008","journal-title":"Int J Infect Dis"},{"key":"R31-20260716","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/brainsci10040227","article-title":"Metronidazole encephalopathy EEG features: a case report with systematic review of the literature.","volume":"10","author":"Ricci","year":"2020","journal-title":"Brain Sci"},{"key":"R32-20260716","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archneur.60.12.1796","article-title":"Metronidazole-induced encephalopathy and inferior olivary hypertrophy: lesion analysis with diffusion-weighted imaging and apparent diffusion coefficient maps.","volume":"60","author":"Seok","year":"2003","journal-title":"Arch Neurol"},{"key":"R33-20260716","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7326\/0003-4819-101-1-92","article-title":"The neurotoxicity of antibacterial agents.","volume":"101","author":"Snavely","year":"1984","journal-title":"Ann Intern Med"},{"key":"R34-20260716","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200201033460117","article-title":"Reversible metronidazole-induced lesions of the cerebellar dentate nuclei.","volume":"346","author":"Woodruff","year":"2002","journal-title":"N Engl J Med"},{"key":"R35-20260716","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/bmj.2.6087.610","article-title":"Metronidazole neuropathy.","volume":"2","author":"Bradley","year":"1977","journal-title":"Br Med J"},{"key":"R36-20260716","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1016\/j.jchromb.2011.09.031","article-title":"Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants.","volume":"879","author":"Cohen-Wolkowiez","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R37-20260716","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1097\/INF.0000000000002698","article-title":"Safety of Metronidazole in Late Pre-term and Term Infants with Complicated Intra-abdominal Infections.","volume":"39","author":"Commander","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R38-20260716","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jpids\/piy040","article-title":"Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study.","volume":"8","author":"Child","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R39-20260716","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003088-198308010-00003","article-title":"Clinical pharmacokinetics of metronidazole.","volume":"8","author":"Ralph","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"R40-20260716","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archinte.1979.03630390027013","article-title":"Metronidazole therapy of anaerobic bacteremia, meningitis, and brain abscess.","volume":"139","author":"Warner","year":"1979","journal-title":"Arch Intern Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:02:18Z","timestamp":1784224938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003726","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,3]]}}}